AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Elongation factor 4 (EF-4) is an elongation factor that is thought to back-translocate on the ribosome during the translation of RNA to proteins. It is found near-universally in bacteria and in eukaryotic endosymbiotic organelles including the mitochondria and the plastid. Responsible for proofreading during protein synthesis, EF-4 is a recent addition to the nomenclature of bacterial elongation factors. Prior to its recognition as an elongation factor, EF-4 was known as leader peptidase A (LepA), as it is the first cistron on the operon carrying the bacterial leader peptidase. In eukaryotes it is traditionally called GUF1 (GTPase of Unknown Function 1). It has the preliminary EC number 3.6.5.n1.
=== Discontinued === 1-Amino-5-bromouracil (ABU) – undefined mechanism of action [60] ABT-418 – nicotinic acetylcholine receptor agonist [61] ABT-436 – vasopressin V1B receptor antagonist [62] Adipiplon (NG-273) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [63] Alnespirone (S-20499) – serotonin 5-HT1A receptor agonist [64] Alosetron (GR-68755; GR-68755C; Lotronex) – serotonin 5-HT3 receptor antagonist [65] Alpidem (Ananxyl; S-800342-001; SL-800342) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [66] Alprazolam lingual spray – GABAA receptor positive allosteric modulator and benzodiazepine [67] AN-788 (IP-2018; NSD788) – serotonin–dopamine reuptake inhibitor (SDRI) [68] AP-521 – serotonin 5-HT1A receptor partial agonist [69] Aprepitant (Emend; L-754030; MK-0869; MK-869; ONO-7436) – neurokinin NK1 receptor antagonist [70] AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist [71] AVN-397 – undefined mechanism of action [72] AZD-2327 – δ-opioid receptor (DOR) agonist [73] AZD-8129 (AR-A000002; AR-A2XX; AR-A2) – serotonin 5-HT1B receptor antagonist [74] Befloxatone (MD-370503) – reversible inhibitor of monoamine oxidase A (RIMA) [75] Blarcamesine (AE-37; ANA001; ANAVEX 2-73) – sigma σ1 receptor agonist, muscarinic acetylcholine M1 receptor agonist, and ionotropic glutamate NMDA receptor agonist [76] Bretazenil (RO-166028) – GABAA receptor positive allosteric modulator and benzodiazepine [77] Brofaromine (Brofaremine; CGP-11305A; Consonar; Consonev) – reversible inhibitor of monoamine oxidase A (RIMA) and serotonin reuptake inhibitor (SRI) [78] Buspirone transdermal (BuSpar Patch) – serotonin 5-HT1A receptor partial agonist and other actions [79] CGS-12066 – serotonin 5-HT1B receptor partial agonist and other actions [80] Coluracetam (BCI-540; MKC-231) – ionotropic glutamate AMPA receptor positive allosteric modulator, choline uptake and acetylcholine synthesis enhancer, and racetam [81] DAA-1097 – translocator protein (TSPO) agonist [82] Devazepide (Devacade; L-364718; MK-329) – Cholecystokinin A (CCKA) receptor antagonist [83] Dipraglurant (ADX-48621; mGluR5-NAM) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [84] Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist [85] Emapunil (AC-5216; XBD173) – translocator protein (TSPO) agonist [86] Emicerfont (GW-876008; GW876008) – corticotropin releasing factor CRF1 receptor antagonist [87] Enciprazine (D-3112; WY-48624) – serotonin 5-HT1A receptor agonist and α1-adrenergic receptor ligand [88] Eplivanserin (Ciltyri; Sliwens; SR-46349; SR-46349B; SR-46615A) – serotonin 5-HT2A receptor antagonist [89] Eptapirone (F-11440) – serotonin 5-HT1A receptor agonist [90] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) [91] Flesinoxan (DU-29373) – serotonin 5-HT1A receptor agonist [92] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [93] Girisopam (EGIS-5810; GYKI-51189) – GABAA receptor positive allosteric modulator and benzodiazepine [94] GT-2203 – histamine H3 receptor agonist [95] Guanfacine (Guanfacine Carrier Wave project; SPD-554) – α2-adrenergic receptor agonist [96] Ipsapirone (BAY-Q-7821; TVX-Q-7821) – serotonin 5-HT1A receptor partial agonist [97] Isamoltane (CGP-361A) – beta blocker (β-adrenergic receptor antagonist) and serotonin 5-HT1A and 5-HT1B receptor antagonist [98] Itasetron (DAU-6215; U-98079) – serotonin 5-HT3 receptor antagonist [99] ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, and μ-opioid receptor (MOR) partial agonist [100] JNJ-19567470 (CRA-5626; R-317573) – corticotropin releasing factor CRF1 receptor antagonist [101] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) ligand [102] Lorazepam intranasal – GABAA receptor positive allosteric modulator and benzodiazepine [103] Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist [104] Midazolam intranasal (ITI-111; midazolam nasal spray; Nayzilam; USL-261) – GABAA receptor positive allosteric modulator and benzodiazepine [105] MK-0777 (L-830982; TPA-023) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/triazolopyridazine [106] NBI-34041 (SB-723620) – corticotropin-releasing hormone (CRH) inhibitor [107] Nerisopam (EGIS-6775; GYKI-52322) – GABAA receptor positive allosteric modulator and benzodiazepine [108] Nivasorexant (ACT-539313; SORA) – orexin OX1 receptor antagonist [109] NS-11821 (NS11821) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [110] Orvepitant (GW-823296; GW823296X) – neurokinin NK1 receptor antagonist [111] Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK3 receptor antagonist [112] Panadiplon (FD-10571; FG-10571; NNC-140571; U-78875) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [113] Pazinaclone (A-77000; DN-2327) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [114] Pozanicline (A-87089.0; ABT-089) – nicotinic acetylcholine receptor agonist [115] Psilocybin (CYB-001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen [116] Research programme: depression and anxiety therapies - Roche/Vernalis – undefined mechanism of action [117] Research programme: GPCR modulators - Nxera Pharma – various actions [118] Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma – monoamine oxidase A (MAO-A) inhibitors [119] Ritanserin (R-55667) – serotonin 5-HT2 receptor antagonist and other actions [120] Robalzotan (AZD-7371; NAD-299) – serotonin 5-HT1A receptor antagonist [121] RS-127445 (MT-500) – serotonin 5-HT2B receptor antagonist [122] SAX-187 (WAY-181187) – serotonin 5-HT6 receptor agonist [123] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist [124] Siramesine (LU-28179) – sigma σ2 receptor agonist [125] SKL-PSY (FZ-016) – serotonin 5-HT1A receptor agonist [126] SSR-241586 (SSR241586) – neurokinin NK2 and NK3 receptor antagonist [127] SUN-8399 – serotonin 5-HT1A receptor agonist [128] Suriclone (RP-31264) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [129] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [130] Tiagabine (A-70569; CEP-6671; Gabitril; NO-050328; NO-328) – GABA transporter 1 (GAT-1) blocker and GABA reuptake inhibitor Troriluzole (BHV-4157; Dazluma; FC-4157; trigriluzole) – various actions (riluzole prodrug) [131] Vestipitant (GW-597599) – neurokinin NK1 receptor antagonist [132] Zabaglurant (TMP-301; TMP301; Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [133] Zalospirone (WY-47846) – serotonin 5-HT1A receptor agonist [134]
Massively parallel reporter assays (MPRAs) and machine learning are newer ways to study gene regulation with reporter genes. One major use is in synthetic biology and gene therapy, where researchers can design better regulatory elements to control gene expression. For example, deep learning models trained on MPRA data have been used to optimize 5' untranslated regions (UTRs) for mRNA translation, enabling tailored designs that enhance gene-editing efficiency in the therapeutic context. This could make mRNA-based treatments more effective, as MPRAs also help identify how genetic variants affect gene expression, which is used in precision medicine and developing personalized treatments. Machine learning models trained on MPRA data can predict how different sequences impact gene activity, making it easier to design reporter genes that respond in specific ways. Combining MPRAs with next-gen sequencing also makes reporter gene experiments faster and more scalable. These advances could even improve mRNA-based vaccines and therapeutics by optimizing untranslated regions (UTRs) to boost stability and translation. For instance, modular MPRAs have uncovered context-specific regulatory sequences linked to type 2 diabetes, revealing enhancer-promoter interactions dependent on cell-specific transcription factors like HNF1. Similarly, MPRA screens of cardiac enhancer variants have pinpointed functional noncoding sequences influencing QT interval variability, directly linking genetic variation to disease-associated gene dysregulation.
A post hoc analysis from a randomized, placebo-controlled, multi-centre study carried out at 11 secondary care centres, as well as a longitudinal single-centre study on pregnant women in Norway, also determined that metformin had no effect on maternal androgens in pregnancies occurring in the setting of PMOS. One systemic review suggested that polymorphisms in the vitamin D receptor gene are associated with the prognosis of polyendocrine metabolic ovarian syndrome, though this is based on small sample sizes and is debated. Studies have shown benefits for vitamin D supplementation in women with vitamin D deficiency and PMOS. Hyperinsulinemia can increase the production of androgens in the ovaries. One context in which this occurs is HAIR-AN syndrome, a rare subtype of PMOS.
Sources: en.wikipedia.org
The first human to human heart transplantation was performed in 1967 by the South African surgeon Christiaan Barnard at Groote Schuur Hospital in Cape Town. This marked an important milestone in cardiac surgery, capturing the attention of both the medical profession and the world at large. However, long-term survival rates of patients were initially very low. Louis Washkansky, the first recipient of a donated heart, died 18 days after the operation while other patients did not survive for more than a few weeks. The American surgeon Norman Shumway has been credited for his efforts to improve transplantation techniques, along with pioneers Richard Lower, Vladimir Demikhov and Adrian Kantrowitz. By mid-2018, the International Society for Heart and Lung Transplantation registry had recorded more than 146,000 heart transplantations worldwide. The first successful transplant of a heart from a genetically modified pig to a human was performed on 7 January 2022 in Baltimore by heart surgeon Bartley P. Griffith. The recipient, 57-year-old David Bennett, survived for 60 days before dying on 8 March 2022. By the middle of the 20th century, heart disease had surpassed infectious disease as the leading cause of death in the United States, and it is currently the leading cause of deaths worldwide. Since 1948, the ongoing Framingham Heart Study has shed light on the effects of various influences on the heart, including diet, exercise, and common medications such as aspirin.
When a protein folds, the titratable amino acids in the protein are transferred from a solution-like environment to an environment determined by the 3-dimensional structure of the protein. For example, in an unfolded protein, an aspartic acid typically is in an environment which exposes the titratable side chain to water. When the protein folds, the aspartic acid could find itself buried deep in the protein interior with no exposure to solvent. Furthermore, in the folded protein, the aspartic acid will be closer to other titratable groups in the protein and will also interact with permanent charges (e.g. ions) and dipoles in the protein. All of these effects alter the pKa value of the amino acid side chain, and pKa calculation methods generally calculate the effect of the protein environment on the model pKa value of an amino acid side chain. Typically, the effects of the protein environment on the amino acid pKa value are divided into pH-independent effects and pH-dependent effects. The pH-independent effects (desolvation, interactions with permanent charges and dipoles) are added to the model pKa value to give the intrinsic pKa value. The pH-dependent effects cannot be added in the same straightforward way and have to be accounted for using Boltzmann summation, Tanford–Roxby iterations or other methods. The interplay of the intrinsic pKa values of a system with the electrostatic interaction energies between titratable groups can produce quite spectacular effects such as non-Henderson–Hasselbalch titration curves and even back-titration effects.
== Fiber type evolution == Almost all multicellular animals depend on muscles to move. Generally, muscular systems of most multicellular animals comprise both slow-twitch and fast-twitch muscle fibers, though the proportions of each fiber type can vary across organisms and environments. The ability to shift their phenotypic fiber type proportions through training and responding to the environment has served organisms well when placed in changing environments either requiring short explosive movements (higher fast twitch proportion) or long duration of movement (higher slow twitch proportion) to survive. Across species, certain gene sequences have been preserved, but do not always have the same functional purpose. Within the zebrafish embryo, the Prdm1 gene down-regulates the formation of new slow twitch fibers through direct and indirect mechanisms such as Sox6 (indirect). In mice, the Prdm1 gene is present but does not control slow muscle genes in mice through Sox6. Bodybuilding has shown that changes in muscle mass and force production can change in a matter of months.
Sources: en.wikipedia.org
=== VUV detectors for gas chromatography detectors === VUV detectors are compatible with most gas chromatography (GC) manufacturers. The detectors can be connected through a heated transfer line inserted through a punch-out in the GC oven casing. A makeup flow of carrier gas is introduced at the end of the transfer line. Analytes arrive in the flow cell and are exposed to VUV light from a deuterium lamp. Specially coated reflective optics paired with a back-thinned charge-coupled device (CCD) enable the collection of high-quality VUV absorption data. Figure 1 shows a schematic of the analyte path from GC to VUV detector.
Bryer defines the Druzes as ghulat of Isma'ilism, as they exaggerated the cult of the al-Hakim bi-Amr Allah and considered him divine. He also defines the Druze as a religion that deviated from Islam, noting that as a result of this deviation, the Druze faith "seems as different from Islam as Islam is from Christianity or Christianity is from Judaism". Despite originating from Isma'ilism, a branch of Islam, the Druze do not consider themselves Muslims, and they do not adhere to the Five Pillars of Islam. In terms of religious comparison, mainstream Christian denominations do not believe in reincarnation or the transmigration of the soul, contrary to the beliefs of the Druze; on the other hand, reincarnation is a paramount tenet in the Druze faith. Christianity teaches evangelism, often through the establishment of missions, unlike the Druze who do not accept converts to their faith. Marriage outside the Druze faith is rare and is strongly discouraged. Similarities between the Druze and Christians include commonalities in their view of monogamous marriage, as well as the forbidding of divorce and remarriage, in addition to the belief in the oneness of God and theophany. The Druze faith incorporates some elements of Christianity, and other religious beliefs.
The cytoskeleton acts to organize and maintain the cell's shape; anchors organelles in place; helps during endocytosis, and in the uptake of external materials by a cell. The cytoskeleton is composed of microtubules, intermediate filaments and microfilaments. There are a great number of proteins associated with them, each controlling a cell's structure by directing, bundling, and aligning filaments. The outermost part of the cytoskeleton is the cell cortex, or actin cortex, a thin layer of cross-linked actomyosins. Its thickness varies with cell type and physiology. It directs the transport through the ER and the Golgi apparatus. The cytoskeleton in the animal cell also plays a part in cytokinesis, in the formation of the spindle apparatus during cell division, the separation of daughter cells.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.